Novavax Inc (NVAX)
$16.24 0.14 (0.87%)
6:53 EDT NVAX Stock Quote Delayed 20 Minutes
Previous Close $16.10
Market Cap 6.20B
PE Ratio -26.62
Volume (Avg. Vol.) 12,012
Day's Range 16.10 - 16.10
52-Week Range 0.34 - 17.71
Dividend & Yield N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
- From InvestorPlace
- From the Web
Investors began buying up NVAX shares in anticipation of the Phase 3 clinical trial announcement. We wound up with a 130% gain on the trade.
Unlike the broader market, these stocks to buy have managed to hold up strong amid the ongoing public health crisis.
Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
Novavax (NVAX) earnings for the vaccine company's fiscal fourth quarter of 2019 have NVAX stock heading higher after-hours Wednesday.
Tesla made its one-millionth car, while Delta expects to save $2 billion in fuel costs. Here's the stock market today.
Boeing shares tanked on more negative reports, while Uber rallied on an asset sale. Here's what happened in the stock market today.
Novavax (NVAX) news for Tuesday concerning the spread of a virus in China has NVAX stock heading higher as more investors pick up the stock.
For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.
Novavax news for Thursday concerning an accelerated approval pathway for one of the company's drugs has NVAX stock soaring higher.
With the major indices showing signs of hesitancy, now is an ideal time to consider lesser-known but viable cheap stocks.
Novavax stock is plunging on Thursday after failing a Phase 3 study. That sets up a breakdown instead of a breakout in NVAX stock.
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut. Com....
As one of the 657 companies in the GICS Health Technology sector Novavax Inc (NASDAQ:NVAX) is a constituent of the 337 company Biotechnology GICS industry group within this sector. NVAX has a market value of $0.6 billion which is in the top half of its industry group. Portfolio Grader's current ranking for NVAX puts it 107 among the 337 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 213 among the 657 companies in the sector, and number 1,498 in the nearly 5,000 company Portfolio Grader universe.
Novavax Inc (NASDAQ:NVAX) ranks in the upper half of its industry group, Biotechnology, and in the upper half of its sector group, Health Technology, with a market value of $0.4 billion. From an investment attractiveness vantage point, NVAX is ranked in the top half of the sector with a ranking of 264 among the 656 companies in the sector; the ranking for NVAX by Portfolio Grader places it 127 among the 337 companies in this industry group, giving it an above-average position and number 1,942 in the 5000 company Portfolio Grader company universe.
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
From The Motley Fool
From Market News Video
Navellier RatingsPowered by Portfolio Grader